chevron_leftBack
As of 5 June 2026, PharmaEngine, Inc. has a market cap of $249.84M USD, ranking #19716 globally and #856 in Taiwan.
It ranks #1778 in the Healthcare sector, and #646 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$249.84MUSD
7.86B TWD
Enterprise Value
$101.23MUSD
3.18B TWD
Revenue (TTM)
$28.97MUSD
911.42M TWD
EBITDA (TTM)
$13.58MUSD
427.21M TWD
Net Income (TTM)
$12.32MUSD
387.64M TWD
EBITDA Margin
47%
Profit Margin
43%
PE Ratio
20.3
Forward PE
19.8
PS Ratio
8.6
PB Ratio
1.6
EV/EBITDA
7.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Hong-Ren Wang
open_in_new
Employees
45
Founded
2002
Website
pharmaengine.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.4% | -1.6% | -6.2% | -19% | -18% | -40% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4162
智擎生技製藥股份有限公司
ISIN: TW0004162003
Shares Out.:
Shares Outstanding:
143.678M1
Shares Float:
117.849M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
54.90 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About PharmaEngine, Inc.
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6446
|
$7.8B
3K%
245.34B TWD
|
48.6
|
|
TWSE: 1795
|
$1.84B
637%
57.95B TWD
|
12.2
|
|
TPEX: 4123
|
$925.55M
270%
29.11B TWD
|
3.4
|
|
TPEX: 6535
|
$809.3M
224%
25.46B TWD
|
-
|
|
TPEX: 4743
|
$789.12M
216%
24.82B TWD
|
-
|
|
TPEX: 4105
|
$584.14M
134%
18.38B TWD
|
11.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
305K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
219K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
144K%
|
97.4
|
|
SIX: RO
|
$324.68B
130K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
116K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
111K%
218.9B CHF
|
20.5
|
chevron_leftBack